{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:46:26Z","timestamp":1793490386094,"version":"4.5.0"},"reference-count":128,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109 -BOT -I-002 -502 -"],"award-info":[{"award-number":["109 -BOT -I-002 -502 -"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Angiosarcomas comprise less than 3% of all soft tissue sarcomas but have a poor prognosis. Most angiosarcomas occur without obvious risk factors but secondary angiosarcoma could arise after radiotherapy or chronic lymphedema. Surgery remains the standard treatment for localized angiosarcoma but neoadjuvant systemic treatment may improve the curability. For advanced angiosarcoma, anthracyclines and taxanes are the main chemotherapy options. Anti-angiogenic agents have a substantial role but the failure of a randomized phase 3 trial of pazopanib with or without an anti-endoglin antibody brings a challenge to future trials in angiosarcomas. Immune checkpoint inhibitors as single agents or in combination with oncolytic virus may play an important role but the optimal duration remains to be investigated. We also report the current understanding of the molecular pathways involved in angiosarcoma pathogenesis including MYC amplification, activation of angiogenic pathways and different molecular alterations that are associated with angiosarcomas of different aetiology. The success of the patient-partnered Angiosarcoma Project (ASCProject) has provided not only detailed insights into the molecular features of angiosarcomas of different origins but also offers a template for future fruitful collaborations between patients, physicians, and researchers. Lastly, we provide our perspective of future developments in optimizing the clinical management of angiosarcomas.<\/jats:p>","DOI":"10.3390\/cancers12113321","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T14:10:41Z","timestamp":1605017441000},"page":"3321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Optimal Clinical Management and the Molecular Biology of Angiosarcomas"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-4029","authenticated-orcid":false,"given":"Tom Wei-Wu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-721X","authenticated-orcid":false,"given":"Jessica","family":"Burns","sequence":"additional","affiliation":[{"name":"Division of Molecular Pathology, The Institute of Cancer Research, London SW3 6JB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London SW3 6JJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Molecular Pathology, The Institute of Cancer Research, London SW3 6JB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1200\/JCO.2009.25.1728","article-title":"Do Radiation-Associated Soft Tissue Sarcomas Have the Same Prognosis As Sporadic Soft Tissue Sarcomas?","volume":"28","author":"Gladdy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1002\/cam4.1698","article-title":"Radiation-associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosarcoma","volume":"7","author":"Salminen","year":"2018","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12105-018-0978-3","article-title":"Characteristics and Prognosis of Primary Head and Neck Angiosarcomas: A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases","volume":"13","author":"Lee","year":"2018","journal-title":"Head Neck Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.athoracsur.2010.03.065","article-title":"Primary cardiac sarcoma","volume":"90","author":"Hamidi","year":"2010","journal-title":"Ann. Thorac. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.21037\/tcr.2019.07.38","article-title":"Angiosarcoma of the breast, the unknown\u2014a review of the current literature","volume":"8","author":"Esposito","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1038\/s41598-020-66579-5","article-title":"Angiosarcoma of bone: A retrospective study of the European Musculoskeletal Oncology Society (EMSOS)","volume":"10","author":"Palmerini","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.19.00129","article-title":"Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort","volume":"37","author":"Turcotte","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/bjc.2017.198","article-title":"Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: A multicenter study","volume":"117","author":"Zhang","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3816\/CBC.2008.n.066","article-title":"BRCA Mutations and the Risk of Angiosarcoma After Breast Cancer Treatment","volume":"8","author":"West","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijrobp.2020.02.020","article-title":"Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer","volume":"107","author":"Schlosser","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ebiom.2019.02.031","article-title":"RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study","volume":"41","author":"Mirjolet","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00008469-200310000-00012","article-title":"Occupational exposure to vinyl chloride and cancer risk: A review of the epidemiologic literature","volume":"12","author":"Bosetti","year":"2003","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005792-197901000-00003","article-title":"The Clinical Features of Hepatic Angiosarcoma: A Report of Four Cases and A Review of the English Literature","volume":"58","author":"Locker","year":"1979","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4890803-5","DOI":"10.1155\/2020\/4890803","article-title":"Axillary Lymph Node Dissection in Angiosarcomas of the Breast: An Asian Institutional Perspective","volume":"2020","author":"Ragavan","year":"2020","journal-title":"Sarcoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1245\/s10434-012-2334-2","article-title":"Cardiac Angiosarcoma Management and Outcomes: 20-Year Single-institution Experience","volume":"19","author":"Hong","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/cam4.1897","article-title":"Primary cardiac sarcomas: A multi-national retrospective review","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.21037\/jtd.2016.08.89","article-title":"Primary pulmonary artery sarcoma: A close associate of pulmonary embolism\u201420-year observational analysis","volume":"8","author":"Bandyopadhyay","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/annonc\/mdm381","article-title":"Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: A retrospective study of 161 cases","volume":"18","author":"Fayette","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jso.23891","article-title":"Neoadjuvant chemotherapy for primary cutaneous\/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection","volume":"111","author":"Oxenberg","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e000787","DOI":"10.1136\/esmoopen-2020-000787","article-title":"Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: A multicentre study","volume":"5","author":"Constantinidou","year":"2020","journal-title":"ESMO Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.athoracsur.2016.10.054","article-title":"Improved Outcomes With the Evolution of a Neoadjuvant Chemotherapy Approach to Right Heart Sarcoma","volume":"104","author":"Ramlawi","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11517","DOI":"10.1200\/JCO.2020.38.15_suppl.11517","article-title":"A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma","volume":"38","author":"Ravi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"v683","DOI":"10.1093\/annonc\/mdz283","article-title":"Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)","volume":"30","author":"Jones","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.ejca.2014.10.004","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials","volume":"50","author":"Young","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Xing, M., Yan, F., Yu, S., and Shen, P. (2015). Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. PLOS ONE, 10.","DOI":"10.1371\/journal.pone.0133569"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1006429907449","article-title":"Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas","volume":"18","author":"Chidiac","year":"2000","journal-title":"Investig. New Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1023\/A:1008439013169","article-title":"A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas","volume":"9","author":"Garcia","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: Results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000381917","article-title":"Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma","volume":"89","author":"Munhoz","year":"2015","journal-title":"Oncology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0923-7534(21)00660-8","article-title":"502O_PR Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium","volume":"27","author":"Chen","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2004.08.043","article-title":"Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma","volume":"22","author":"Leu","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2008.07.037","article-title":"Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group","volume":"44","author":"Schlemmer","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fujisawa, Y., Fujimura, T., Matsushita, S., Yamamoto, Y., Uchi, H., Otsuka, A., Funakoshi, T., Miyagi, T., Hata, H., and Gosho, M. (2020). The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: A multicentre prospective observational study. Br. J. Dermatol.","DOI":"10.1111\/bjd.19042"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/SRCM\/2006\/15947","article-title":"A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas","volume":"2006","author":"Anderson","year":"2006","journal-title":"Sarcoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","article-title":"Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study","volume":"6","author":"Pasquier","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: A retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/532478","article-title":"Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma","volume":"2015","author":"Dickson","year":"2015","journal-title":"Sarcoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ng.2921","article-title":"Recurrent PTPRB and PLCG1 mutations in angiosarcoma","volume":"46","author":"Behjati","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/PAS.0000000000000582","article-title":"Recurrent CIC Gene Abnormalities in Angiosarcomas","volume":"40","author":"Huang","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial","volume":"33","author":"Bompas","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_47","first-page":"260","article-title":"Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF\/GETO)","volume":"17","author":"Italiano","year":"2012","journal-title":"Oncology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_49","first-page":"88","article-title":"Pazopanib in advanced vascular sarcomas: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Jones","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.critrevonc.2019.04.010","article-title":"Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease","volume":"138","author":"Weidema","year":"2019","journal-title":"Crit. Rev. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2013.43","article-title":"Expression of angiopoietin-TIE system components in angiosarcoma","volume":"26","author":"Buehler","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00280-015-2689-8","article-title":"Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma","volume":"75","author":"Angelo","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2019.07.024","article-title":"Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours","volume":"120","author":"Jones","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-013-0365-x","article-title":"Endoglin for Targeted Cancer Treatment","volume":"16","author":"Rosen","year":"2014","journal-title":"Curr. Oncol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/onc.2010.418","article-title":"Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma","volume":"30","author":"Pardali","year":"2010","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1200\/JCO.2016.34.15_suppl.11016","article-title":"A phase 1B\/phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS)","volume":"34","author":"Attia","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdy464","article-title":"An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)","volume":"30","author":"Mehta","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0000000000000317","article-title":"Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma","volume":"43","author":"Gambichler","year":"2020","journal-title":"J. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1253657","DOI":"10.1080\/2162402X.2016.1253657","article-title":"Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma","volume":"6","author":"Honda","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JGO.2016.005843","article-title":"Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma","volume":"3","author":"Shimizu","year":"2017","journal-title":"J. Glob. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ijc.28581","article-title":"CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma","volume":"134","author":"Fujii","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: A case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1747340","DOI":"10.1080\/2162402X.2020.1747340","article-title":"Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas","volume":"9","author":"Dancsok","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"Mahoney","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: A single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0560.2011.01843.x","article-title":"FISH for MYC amplification and anti-MYC immunohistochemistry: Useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations","volume":"39","author":"Fernandez","year":"2011","journal-title":"J. Cutan. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2353\/ajpath.2010.090637","article-title":"MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema","volume":"176","author":"Manner","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/modpathol.2011.134","article-title":"Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: Clinicopathological, immunohistochemical and molecular analysis of 66 cases","volume":"25","author":"Mentzel","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/cup.12278","article-title":"Fully automated dual-color dual-hapten silverin situhybridization staining forMYCamplification: A diagnostic tool for discriminating secondary angiosarcoma","volume":"41","author":"Ko","year":"2014","journal-title":"J. Cutan. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/carcin\/bgs155","article-title":"A transcriptome signature of endothelial lymphatic cells coexists with the chronic oxidative stress signature in radiation-induced post-radiotherapy breast angiosarcomas","volume":"33","author":"Almeida","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/gcc.21943","article-title":"The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification","volume":"51","author":"Italiano","year":"2012","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_75","unstructured":"Orrock, J., Wu, T., Folpe, A., and William, S. (2012). Immunohistochemistry (IHC) for c-Myc in the differential diagnosis of vascular tumors of the liver. Laboratory Investigation, Nature Publishing Group."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/modpathol.2013.163","article-title":"MYC amplification and overexpression in primary cutaneous angiosarcoma: A fluorescence in-situ hybridization and immunohistochemical study","volume":"27","author":"Shon","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/DAD.0000000000001053","article-title":"Immunohistochemical and Fluorescence In Situ Hybridization Analysis of MYC in a Series of 17 Cutaneous Angiosarcomas","volume":"40","author":"Requena","year":"2018","journal-title":"Am. J. Dermatopathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canrad.2015.01.001","article-title":"Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?","volume":"19","author":"Lebel","year":"2015","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/ng1855","article-title":"Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster","volume":"38","author":"Dews","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/nat.2013.0467","article-title":"Multiple microRNAs Derived from Chemically Synthesized Precursors Regulate Thrombospondin 1 Expression","volume":"24","author":"Dogar","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1002\/cncr.27614","article-title":"Alterations of the p53 and PIK3CA\/AKT\/mTOR pathways in angiosarcomas","volume":"118","author":"Italiano","year":"2012","journal-title":"Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<952::AID-IJC7>3.0.CO;2-X","article-title":"Mutations of p53 tumor-suppressor gene in angiosarcoma","volume":"71","author":"Naka","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"36041","DOI":"10.18632\/oncotarget.5936","article-title":"Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway","volume":"6","author":"Murali","year":"2015","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/carcin\/16.11.2879","article-title":"p53 Mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure","volume":"16","author":"Soini","year":"1995","journal-title":"Carcinogenesis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/hupa.2002.126880","article-title":"Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver","volume":"33","author":"Weihrauch","year":"2002","journal-title":"Hum. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/798403","article-title":"Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases","volume":"2013","author":"Hung","year":"2013","journal-title":"Sarcoma"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0002-9440(10)65729-X","article-title":"MDM-2 Oncoprotein Overexpression, p53 Gene Mutation, and VEGF Up-Regulation in Angiosarcomas","volume":"153","author":"Zietz","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_88","first-page":"215","article-title":"Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours","volume":"356","author":"Donehower","year":"1992","journal-title":"Nat. Cell Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"dmm038612","DOI":"10.1242\/dmm.038612","article-title":"Development of mouse models of angiosarcoma driven by p53","volume":"12","author":"Salter","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-9822(00)00002-6","article-title":"Tumor spectrum analysis in p53-mutant mice","volume":"4","author":"Jacks","year":"1994","journal-title":"Curr. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ignatius, M.S., Hayes, M.N., E Moore, F., Tang, Q., Garcia, S.P., Blackburn, P.R., Baxi, K., Wang, L., Jin, A., and Ramakrishnan, A. (2018). tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. eLife, 7.","DOI":"10.7554\/eLife.37202"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/gcc.20827","article-title":"Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions","volume":"50","author":"Guo","year":"2011","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1158\/0008-5472.CAN-09-2068","article-title":"KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors","volume":"69","author":"Antonescu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41379-020-0511-6","article-title":"Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis","volume":"33","author":"Beca","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1158\/0008-5472.CAN-14-1162","article-title":"A Recurrent Activating PLCG1 Mutation in Cardiac Angiosarcomas Increases Apoptosis Resistance and Invasiveness of Endothelial Cells","volume":"74","author":"Kunze","year":"2014","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jso.20766","article-title":"Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas","volume":"97","author":"Itakura","year":"2007","journal-title":"J. Surg. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"a026609","DOI":"10.1101\/cshperspect.a026609","article-title":"The PI3K-PKB\/Akt Pathway","volume":"7","author":"Hemmings","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: Mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1265-1","article-title":"The roles of nuclear focal adhesion kinase (FAK) on Cancer: A focused review","volume":"38","author":"Zhou","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1038\/sj.onc.1202992","article-title":"Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2","volume":"18","author":"Fachinger","year":"1999","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1083\/jcb.200811159","article-title":"VE-PTP controls blood vessel development by balancing Tie-2 activity","volume":"185","author":"Winderlich","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.str.2012.09.005","article-title":"Structural and Functional Integration of the PLC\u03b3 Interaction Domains Critical for Regulatory Mechanisms and Signaling Deregulation","volume":"20","author":"Bunney","year":"2012","journal-title":"Structure"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: Enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-018-0605-7","article-title":"Genomics of response to immune checkpoint therapies for cancer: Implications for precision medicine","volume":"10","author":"Conway","year":"2018","journal-title":"Genome Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/0008-5472.CAN-07-0426","article-title":"Myc Goes Global: New Tricks for an Old Oncogene: Figure 1","volume":"67","author":"Knoepfler","year":"2007","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"a014241","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC Activation Is a Hallmark of Cancer Initiation and Maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1101\/gad.1024602","article-title":"c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression","volume":"16","author":"Baudino","year":"2002","journal-title":"Genes Dev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcell.2017.00035","article-title":"In vivo Reprogramming of Cancer Metabolism by MYC","volume":"5","author":"Camarda","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10450","DOI":"10.1073\/pnas.1409778111","article-title":"Alteration of the lipid profile in lymphomas induced by MYC overexpression","volume":"111","author":"Eberlin","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/sj.onc.1201138","article-title":"Myc represses the growth arrest gene gadd45","volume":"14","author":"Marhin","year":"1997","journal-title":"Oncogene"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2478\/s11658-009-0001-9","article-title":"The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo","volume":"14","author":"Zhang","year":"2009","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas","volume":"171","author":"Abeshouse","year":"2017","journal-title":"Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.2353\/ajpath.2010.100104","article-title":"Constant p53 Pathway Inactivation in a Large Series of Soft Tissue Sarcomas with Complex Genetics","volume":"177","author":"Chibon","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/1078-0432.CCR-10-2050","article-title":"Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis","volume":"17","author":"Ito","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"9335","DOI":"10.1074\/jbc.M109955200","article-title":"Absence of Erythrogenesis and Vasculogenesis inPlcg1-deficient Mice","volume":"277","author":"Liao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.emboj.7601532","article-title":"A MAPK docking site is critical for downregulation of Capicua by Torso and EGFR RTK signaling","volume":"26","author":"Astigarraga","year":"2007","journal-title":"EMBO J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/BJ20101562","article-title":"ERK\/p90RSK\/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capic\u00faa","volume":"433","author":"Dissanayake","year":"2011","journal-title":"Biochem. J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/carcin\/bgr064","article-title":"A transcriptome signature distinguished sporadic from postradiotherapy radiation-induced sarcomas","volume":"32","author":"Ugolin","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41379-019-0300-2","article-title":"Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas","volume":"32","author":"Lesluyes","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/dvdy.10163","article-title":"Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate","volume":"225","author":"Hong","year":"2002","journal-title":"Dev. Dyn."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1093\/emboj\/cdg342","article-title":"T1\/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema","volume":"22","author":"Schacht","year":"2003","journal-title":"EMBO J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pathophys.2009.10.004","article-title":"VEGF-mediated signal transduction in lymphatic endothelial cells","volume":"17","author":"Bahram","year":"2010","journal-title":"Pathophysiology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:31:35Z","timestamp":1760178695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":128,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113321"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113321","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}